NYSE:CRY - Cryolife Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $29.30 -0.35 (-1.18 %) (As of 07/16/2018 04:00 PM ET)Previous Close$29.65Today's Range$29.15 - $29.6552-Week Range$16.80 - $30.45Volume103,700 shsAverage Volume123,402 shsMarket Capitalization$1.09 billionP/E Ratio73.25Dividend YieldN/ABeta0.78 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia. Receive CRY News and Ratings via Email Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNYSE:CRY CUSIP22890310 Webwww.cryolife.com Phone770-419-3355 Debt Debt-to-Equity Ratio0.77 Current Ratio5.07 Quick Ratio3.72 Price-To-Earnings Trailing P/E Ratio73.25 Forward P/E Ratio101.03 P/E GrowthN/A Sales & Book Value Annual Sales$189.70 million Price / Sales5.66 Cash Flow$0.6963 per share Price / Cash42.08 Book Value$8.28 per share Price / Book3.54 Profitability EPS (Most Recent Fiscal Year)$0.40 Net Income$3.70 million Net Margins-1.15% Return on Equity4.55% Return on Assets2.50% Miscellaneous Employees1,000 Outstanding Shares36,630,000Market Cap$1,086.14 Cryolife (NYSE:CRY) Frequently Asked Questions What is Cryolife's stock symbol? Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY." How were Cryolife's earnings last quarter? Cryolife Inc (NYSE:CRY) released its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.02 EPS for the quarter, meeting the consensus estimate of $0.02. The medical equipment provider earned $61.95 million during the quarter, compared to the consensus estimate of $60.30 million. Cryolife had a negative net margin of 1.15% and a positive return on equity of 4.55%. The business's revenue was up 37.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.09 EPS. View Cryolife's Earnings History. When is Cryolife's next earnings date? Cryolife is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for Cryolife. What guidance has Cryolife issued on next quarter's earnings? Cryolife issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $0.29-0.32 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.31. The company issued revenue guidance of $250-256 million, compared to the consensus revenue estimate of $252.86 million. What price target have analysts set for CRY? 3 equities research analysts have issued 1 year price objectives for Cryolife's shares. Their forecasts range from $23.50 to $28.00. On average, they anticipate Cryolife's share price to reach $25.8333 in the next twelve months. This suggests that the stock has a possible downside of 11.8%. View Analyst Ratings for Cryolife. What is the consensus analysts' recommendation for Cryolife? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Cryolife stock? Here are some recent quotes from research analysts about Cryolife stock: 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (7/10/2018) 2. Northland Securities analysts commented, "SER-109 stumbles do not impact the long game, in our view. To us, the attractiveness of MCRB’s C. difficile infection (CDI) programs is more about establishing proof of concept (POC) that the microbiome can be manipulated for therapeutic purposes than their revenue potential. If the IBD and/or cancer immunotherapy programs are successful, we believe far larger commercial opportunities could emerge." (3/8/2018) 3. Canaccord Genuity analysts commented, "We are updating our model and now include 2019 estimates. We reiterate our BUY rating and $25 price target." (1/3/2018) Who are some of Cryolife's key competitors? Some companies that are related to Cryolife include Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Nevro (NVRO), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), OraSure Technologies (OSUR) and Intersect ENT (XENT). Who are Cryolife's key executives? Cryolife's management team includes the folowing people: Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 51)Mr. David Ashley Lee, Exec. VP, COO & CFO (Age 53)Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 53)Ms. Amy D. Horton, VP & Chief Accounting Officer (Age 48) Has Cryolife been receiving favorable news coverage? Media coverage about CRY stock has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cryolife earned a media sentiment score of 0.17 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 45.84 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Cryolife? Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cryolife's stock price today? One share of CRY stock can currently be purchased for approximately $29.30. How big of a company is Cryolife? Cryolife has a market capitalization of $1.09 billion and generates $189.70 million in revenue each year. The medical equipment provider earns $3.70 million in net income (profit) each year or $0.40 on an earnings per share basis. Cryolife employs 1,000 workers across the globe. How can I contact Cryolife? Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355. MarketBeat Community Rating for Cryolife (NYSE CRY)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 225 (Vote Outperform)Underperform Votes: 155 (Vote Underperform)Total Votes: 380MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?